(PharmaNewsWire.Com, August 25, 2020 ) Factors such as growing drug & alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing, and regulatory approvals and new product & service launches are driving the growth of the market.
The drug screening market was valued at USD 4.86 Billion in 2016 and is expected to reach USD 8.63 Billion by 2022, growing at a CAGR of 10.2% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.
Drug abuse and alcohol consumption are increasing across the globe. According to the United Nations Office on Drugs and Crime (UNODC), in 2015, about 5% of the global adult population consumed drugs at least once. Also, 0.6% of the global adult population suffers from drug use disorders. The extent of harm caused by drugs is equal to losing 28 million years of “healthy” life (disability-adjusted life years [DALYs]), globally.
The growth of the global drug screening market is primarily influenced by the following factors:
# Growing Drug & Alcohol Consumption # Enforcement of Stringent Laws Mandating Drug and Alcohol Testing # Presence of Government Funding in Major Markets # Regulatory Approvals & Product Launches and Services
Based on product, the market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2017.
The global market by sample type is segmented into urine, breath, oral fluid, hair, and other samples. The urine sample segment is estimated to account for the largest share in 2017, however, the oral fluid samples segment is expected to register the highest growth rate during the forecast period.
Based on end users, the market is segmented into workplaces, criminal justice systems and law enforcement, drug treatment centers, pain management centers, schools and colleges, hospitals, individual users, and drug testing laboratories. In 2017, the workplace testing segment is expected to account for the largest share of the market. The growth of this end-user segment can be attributed to the growing safety concerns in the workplace and the increasing number of organizations that have made regular drug screening mandatory.
Geographical growth scenario of Anatomic Pathology Market:
The market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption. Leading market players and strategies adopted
The Drug Screening Market is highly competitive with presence of several big and small players. Prominent players offering drug screening products include Alere (US), Thermo Fisher (US), Drägerwerk (Germany), OraSure (US), Alfa Scientific Designs (US), Lifeloc (US), MPD, Inc. (US), Premier Biotech (US), Shimadzu (Japan), Siemens Healthineers (US). While, LabCorp (US), Quest Diagnostics (US), Omega Laboratories (US), Psychemedics (US), CRL (US), SureHire (Canada), and CannAmm (Canada) are some of key players offering drug screening services.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
